Shortcuts

open access

Vol 9, No 4 (2010)
Case reports
Published online: 2011-02-02
Get Citation

Management of androgen-ablation refractory prostate cancer. Role for somatostatin analogues?

Suleika J. Rohd-Thomsen, Lia van der Plaat, Zbigniew Zylicz
Advances in Palliative Medicine 2010;9(4):145-148.

open access

Vol 9, No 4 (2010)
Case reports
Published online: 2011-02-02

Abstract

Patients with metastasised prostate cancer survive longer with anti-androgen therapy but eventually all progress into the androgen-ablation refractory (AAR) stage and die. There are only few effective strategies to treat patients with AAR cancers and they include even more effective androgen blockade by for example glucocorticoids or ketoconazole. Some of the tumours differentiate into neuroendocrine tumours and become completely independent of androgen stimulation. It is believed that these tumours over-express somatostatin receptors which may be a new target for the anti-tumour treatment. In this article we present a patient with advanced AAR prostate cancer and intractable retching and vomiting. As the last resort, he was treated with octreotide SC which resulted rapid amelioration of the symptoms and in significantly decreased PSA which could be translated into longer survival. In this article we review rationale for the use of somatostatin analogues in the treatment of patients with hormone-refractory prostate cancer.

Adv. Pall. Med. 2010; 9, 4: 145–150

Abstract

Patients with metastasised prostate cancer survive longer with anti-androgen therapy but eventually all progress into the androgen-ablation refractory (AAR) stage and die. There are only few effective strategies to treat patients with AAR cancers and they include even more effective androgen blockade by for example glucocorticoids or ketoconazole. Some of the tumours differentiate into neuroendocrine tumours and become completely independent of androgen stimulation. It is believed that these tumours over-express somatostatin receptors which may be a new target for the anti-tumour treatment. In this article we present a patient with advanced AAR prostate cancer and intractable retching and vomiting. As the last resort, he was treated with octreotide SC which resulted rapid amelioration of the symptoms and in significantly decreased PSA which could be translated into longer survival. In this article we review rationale for the use of somatostatin analogues in the treatment of patients with hormone-refractory prostate cancer.

Adv. Pall. Med. 2010; 9, 4: 145–150

Get Citation

Keywords

prostate cancer; hormone-refractory prostate cancer; somatostatin analogues; octreotide; lanreotide; vomiting; retching

About this article
Title

Management of androgen-ablation refractory prostate cancer. Role for somatostatin analogues?

Journal

Advances in Palliative Medicine

Issue

Vol 9, No 4 (2010)

Pages

145-148

Published online

2011-02-02

Bibliographic record

Advances in Palliative Medicine 2010;9(4):145-148.

Keywords

prostate cancer
hormone-refractory prostate cancer
somatostatin analogues
octreotide
lanreotide
vomiting
retching

Authors

Suleika J. Rohd-Thomsen
Lia van der Plaat
Zbigniew Zylicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl